No Data
Ling Rui Pharmaceutical 2024 Annual Report
Summary of Lingrui Pharmaceutical\'s 2024 Annual Report
Lingrui Pharmaceutical\'s 2025 First Quarter Report
Henan Lingrui Pharmaceutical (600285.SH): In the first quarter, the net income was 0.217 billion yuan, an increase of 13.89% year-on-year.
Glory Financial announced on April 25 that Henan Lingrui Pharmaceutical (600285.SH) published its first-quarter report for 2025, achieving revenue of 1.021 billion yuan, a year-on-year increase of 12.29%; Net income attributable to shareholders of the listed company was 0.217 billion yuan, a year-on-year increase of 13.89%; EPS was 0.383 yuan.
While Institutions Invested in Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Benefited From Last Week's 3.2% Gain, Retail Investors Stood to Gain the Most
Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Low P/E No Reason For Excitement
Are Robust Financials Driving The Recent Rally In Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Stock?
